Valvular Heart Disease

December 16, 2022

An analysis of data from randomized clinical trials and non-randomized trials comparing TAVI and surgery provides an overview of 5-year incidence, outcomes, and predictors of structural valve deterioration with both approaches.

November 03, 2022

Released on Nov. 2, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease were created to be used concurrently with guidance published in 2020 and to replace previous guidance published in 2010 and 2015.

September 24, 2022

The final weekend of each month, our editorial staff compiles a list of our most popular content from the past month. The top content from September 2022 includes trio of FDA approvals, a TCT headliner, a look back at ESC Congress 22, and a new prognostic biomarker for heart failure.

September 19, 2022

Data from the CLASP IID trial provide insight into the benefits of the PASCAL TEER system for degenerative mitral regurgitation, which demonstrated noninferiority to the MitraClip system for the trial's primary safety and efficacy endpoints.

September 17, 2022

Results of the PROTECTED TAVR trial suggest use of cerebral embolic protection devices was not associated with a reduction in risk of stroke within the first 72 hours after TAVR or prior to hospital discharge among patients with aortic stenosis.

September 16, 2022

Announced on September 15 by Edwards Lifesciences Corporation, the PASCAL Precision transcatheter valve repair system has received approval for transcatheter edge-to-edge repair in patients with degenerative mitral regurgitation.

September 13, 2022

A budget impact analysis details the benefits of TAVR compared with SAVR from the hospital payers' perspective among patients with low-risk aortic stenosis.

August 31, 2022

A new study provides insight into contemporary trends in gender- and income-based disparities in 30-day mortality risk following cardiac surgery among patients in the US.

August 04, 2022

An analysis of data from the PARTNERS trials and registries details associations between early LVEF improvement following TAVR and 5-year outcomes, including risk of all-cause and cardiovascular mortality.

July 30, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.